Literature DB >> 16973581

Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection.

Louise Jones1, Antony P Black, Gathsaurie N Malavige, Graham S Ogg.   

Abstract

Open reading frame 4 (ORF4) of varicella-zoster virus (VZV) encodes an immediate-early protein that is believed to be important for viral infectivity and establishing latency. Evidence suggests that VZV-specific T cells are crucial in the control of viral replication, but there are no data addressing the existence of potential ORF4 protein-specific CD4+ T cells. We tested the hypothesis that VZV ORF4 protein-specific CD4+ T cells could be identified and characterized within the peripheral blood of healthy immune donors following primary infection. Gamma interferon (IFN-gamma) immunosorbent assays were used to screen peripheral blood mononuclear cells obtained from healthy seropositive donors for responses to overlapping ORF4 peptides, viral lysate, and live vaccine. High frequencies of ORF4 protein-specific T cells were detected ex vivo in individuals up to 52 years after primary infection. Several immunogenic regions of the ORF4 protein were identified, including a commonly recognized epitope which was restricted through HLA-DRB1*07. Total ORF4 protein-specific responses comprised 19.7% and 20.7% of the total lysate and vaccine responses, respectively, and were dominated by CD4+ T cells. Indeed, CD4+ T cells were found to dominate the overall virus-specific IFN-gamma cellular immune response both ex vivo and after expansion in vitro. In summary, we have identified an ORF4 protein as a novel target antigen for persistent VZV-specific CD4+ T cells, with implications for disease pathogenesis and future vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973581      PMCID: PMC1617243          DOI: 10.1128/JVI.00564-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Varicella-zoster virus productively infects mature dendritic cells and alters their immune function.

Authors:  Gavin Morrow; Barry Slobedman; Anthony L Cunningham; Allison Abendroth
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

2.  Varicella-zoster virus-specific cytotoxic T lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human peripheral blood.

Authors:  J K Hickling; L K Borysiewicz; J G Sissons
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

3.  Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170.

Authors:  A M Arvin; E Kinney-Thomas; K Shriver; C Grose; C M Koropchak; E Scranton; A E Wittek; P S Diaz
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

4.  Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection.

Authors:  A M Arvin; C M Koropchak; B R Williams; F C Grumet; S K Foung
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

5.  The complete DNA sequence of varicella-zoster virus.

Authors:  A J Davison; J E Scott
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

6.  T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine.

Authors:  P S Diaz; S Smith; E Hunter; A M Arvin
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

7.  Varicella-zoster virus-specific HLA-restricted cytotoxicity of normal immune adult lymphocytes after in vitro stimulation.

Authors:  E C Cooper; L K Vujcic; G V Quinnan
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

8.  Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency.

Authors:  Jeffrey I Cohen; Tammy Krogmann; Jeffrey P Ross; Lesley Pesnicak; Elena A Prikhod'ko
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  Stress-induced subclinical reactivation of varicella zoster virus in astronauts.

Authors:  Satish K Mehta; Randall J Cohrs; Bagher Forghani; Gary Zerbe; Donald H Gilden; Duane L Pierson
Journal:  J Med Virol       Date:  2004-01       Impact factor: 2.327

10.  Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination.

Authors:  Christian R Frey; Margaret A Sharp; Andrew S Min; D Scott Schmid; Vladimir Loparev; Ann M Arvin
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

View more
  17 in total

1.  Development of an IFN-γ ELISpot assay to assess varicella-zoster virus-specific cell-mediated immunity following umbilical cord blood transplantation.

Authors:  Insaf Salem Fourati; Anne-Julie Grenier; Élyse Jolette; Natacha Merindol; Philippe Ovetchkine; Hugo Soudeyns
Journal:  J Vis Exp       Date:  2014-07-09       Impact factor: 1.355

2.  Perspectives on vaccines against varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.

Authors:  Adriana Weinberg; Jennifer Canniff; Nadine Rouphael; Aneesh Mehta; Mark Mulligan; Jennifer A Whitaker; Myron J Levin
Journal:  J Immunol       Date:  2017-06-12       Impact factor: 5.422

4.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

5.  Identification of varicella-zoster virus-specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation.

Authors:  Pim L J van der Heiden; Renate de Boer; Dirk M van der Steen; Michel G D Kester; Menno W A G van der Hoorn; Wilmy M E Haarman; Helen E Barnby-Porritt; Jeremy W Fry; C E Napper; Erik W A Marijt; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

6.  Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.

Authors:  G N Malavige; L Jones; A P Black; G S Ogg
Journal:  Clin Exp Immunol       Date:  2008-03-20       Impact factor: 4.330

7.  Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques.

Authors:  Kristen Haberthur; Aubrey Kraft; Nicole Arnold; Byung Park; Christine Meyer; Mark Asquith; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 8.  T-cell immunity to human alphaherpesviruses.

Authors:  Werner J D Ouwendijk; Kerry J Laing; Georges M G M Verjans; David M Koelle
Journal:  Curr Opin Virol       Date:  2013-05-08       Impact factor: 7.090

9.  Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans.

Authors:  Ilhem Messaoudi; Alexander Barron; Mary Wellish; Flora Engelmann; Alfred Legasse; Shannon Planer; Don Gilden; Janko Nikolich-Zugich; Ravi Mahalingam
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

10.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.